drugset / Trial / NCT03232619
CD19-CART Treatment for ALL
Phase 1/2
Completed
4 enrolled
Bioray Laboratories
Second Xiangya Hospital of Central South University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and efficacy of a novel CD19-CART in the treatment of refractory or recurrent ALL.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2020-05-06
- Completion
- 2020-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T | Cell therapy | 500000 cells/kg | — |
| Subject | CD19 CAR-T | Cell therapy | 5e+06 cells/kg | — |